# Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

> **NCT03647358** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Thyroid Carcinoma
- Metastatic Thyroid Carcinoma

## Interventions

- **DEVICE:** PET/CT Scan
- **DRUG:** Iodine-124

## Key facts

- **NCT ID:** NCT03647358
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-21
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647358, "Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03647358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*